ReGenX Biosciences
A leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy.
Launch date
Employees
Market cap
AUD981m
Enterprise valuation
AUD664m (Public information from Sep 2024)
Share price
$12.53 RGNX
Rockville Maryland (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 155m | 470m | 113m | 90.2m | 92.2m | 282m | 233m |
% growth | 339 % | 204 % | (76 %) | (20 %) | 2 % | 206 % | (17 %) |
EBITDA | (115m) | 161m | (263m) | (251m) | (200m) | (5.7m) | (153m) |
% EBITDA margin | (74 %) | 34 % | (233 %) | (278 %) | (217 %) | (2 %) | (66 %) |
Profit | (111m) | 128m | (280m) | (263m) | (226m) | (85.7m) | (133m) |
% profit margin | (72 %) | 27 % | (249 %) | (292 %) | (245 %) | (30 %) | (57 %) |
EV / revenue | 7.9x | 2.0x | 5.5x | 5.7x | 5.0x | 1.6x | 2.0x |
EV / EBITDA | -10.6x | 5.9x | -2.4x | -2.0x | -2.3x | -78.3x | -3.1x |
R&D budget | 166m | 181m | 242m | 232m | - | - | - |
R&D % of revenue | 108 % | 39 % | 215 % | 257 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$2.8m | Grant | ||
$7.7m | Grant | ||
N/A | $7.9m | Early VC | |
$30.0m | Series C | ||
$70.5m | Series D | ||
N/A | N/A | IPO | |
N/A | $87.2m | Post IPO Equity | |
* | N/A | $202m | Post IPO Equity |
N/A | Post IPO Equity | ||
* | N/A | $230m | Post IPO Equity |
* | N/A | $140m | Post IPO Equity |
Total Funding | AUD184m |
Related Content
Recent News about ReGenX Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.